TY - JOUR
T1 - Liquid Biopsy versus CT
T2 - Comparison of Tumor Burden Quantification in 1065 Patients with Metastases
AU - Dawi, Lama
AU - Belkouchi, Younes
AU - Lawrance, Littisha
AU - Gautier, Othilie
AU - Ammari, Samy
AU - Vasseur, Damien
AU - Wirth, Felix
AU - Hadchiti, Joya
AU - Morer, Salome
AU - David, Clemence
AU - Bidault, François
AU - Balleyguier, Corinne
AU - Kind, Michèle
AU - Bayle, Arnaud
AU - Belcaid, Laila
AU - Aldea, Mihaela
AU - Nicotra, Claudio
AU - Geraud, Arthur
AU - Sakkal, Madona
AU - Blanc-Durand, Felix
AU - Moog, Sophie
AU - Mosele, Maria Fernanda
AU - Tagliamento, Marco
AU - Bernard-Tessier, Alice
AU - Verret, Benjamin
AU - Smolenschi, Cristina
AU - Auger, Nathalie
AU - Gazzah, Anas
AU - Micol, Jean Baptiste
AU - Caron, Olivier
AU - Hollebecque, Antoine
AU - Loriot, Yohann
AU - Besse, Benjamin
AU - Lacroix, Ludovic
AU - Rouleau, Etienne
AU - Ponce, Santiago
AU - André, Fabrice
AU - Soria, Jean Charles
AU - Barlesi, Fabrice
AU - Muller, Serge
AU - Cournede, Paul Henry
AU - Talbot, Hugues
AU - Italiano, Antoine
AU - Lassau, Nathalie
N1 - Publisher Copyright:
© RSNA, 2024.
PY - 2024/11/1
Y1 - 2024/11/1
N2 - Background: Tumor fraction (TF) at liquid biopsy is a potential noninvasive marker for tumor burden, but validation is needed. Purpose: To evaluate TF as a potential surrogate for tumor burden, assessed at contrast-enhanced CT across diverse metastatic cancers. Methods: This retrospective monocentric study included patients with cancer and metastatic disease, with TF results and contemporaneous contrast-enhanced CT performed between January 2021 and January 2023. The total tumor volume (TTV), representing CT tumor burden, was calculated by adding all lesion volumes and was computed by using manually outlined annotations of each lesion on the largest surface of the axial slice. TF greater than 10% was considered high. A training-validation split was applied. Correlations between TF and TTV were assessed using regression models and Spearman correlation coefficients. Receiver operating characteristic curve analysis established the TTV cutoff. The metastatic site, histology type, and TTV were used to predict liquid biopsy contributory status. Results: Among 1065 patients (median age, 62 years [IQR: 53, 70]; 537 female), 56 288 lesions were annotated, mostly in the lung (n = 20 334), lymph nodes (n = 11 651), and liver (n = 10 277). A total of 763 liquid biopsies were contributive, 254 were noncontributive, and 48 failed. The training and validation sets included 745 and 320 patients, respectively. TF helped predict TTV with the linear model (R2 = 0.17; ρ = 0.41; P < .001). The TTV and TF categories achieved an area under the receiver operating characteristic curve (AUC) of 0.74 (95% CI: 0.71, 0.78), with an optimal cutoff of 151 cm3 for TTV and a TF cutoff of 10%. The sensitivity was 57% (204 of 359) and the specificity was 80% (525 of 658). TTV helped predict contributory status, with an AUC of 0.71 (95% CI: 0.67, 0.76) and an optimal cutoff greater than 37 cm3. Liver lesion volumes were significantly associated with a contributory liquid biopsy in the validation cohort. Conclusion: While correlated, TF at liquid biopsy did not accurately represent the TTV at CT.
AB - Background: Tumor fraction (TF) at liquid biopsy is a potential noninvasive marker for tumor burden, but validation is needed. Purpose: To evaluate TF as a potential surrogate for tumor burden, assessed at contrast-enhanced CT across diverse metastatic cancers. Methods: This retrospective monocentric study included patients with cancer and metastatic disease, with TF results and contemporaneous contrast-enhanced CT performed between January 2021 and January 2023. The total tumor volume (TTV), representing CT tumor burden, was calculated by adding all lesion volumes and was computed by using manually outlined annotations of each lesion on the largest surface of the axial slice. TF greater than 10% was considered high. A training-validation split was applied. Correlations between TF and TTV were assessed using regression models and Spearman correlation coefficients. Receiver operating characteristic curve analysis established the TTV cutoff. The metastatic site, histology type, and TTV were used to predict liquid biopsy contributory status. Results: Among 1065 patients (median age, 62 years [IQR: 53, 70]; 537 female), 56 288 lesions were annotated, mostly in the lung (n = 20 334), lymph nodes (n = 11 651), and liver (n = 10 277). A total of 763 liquid biopsies were contributive, 254 were noncontributive, and 48 failed. The training and validation sets included 745 and 320 patients, respectively. TF helped predict TTV with the linear model (R2 = 0.17; ρ = 0.41; P < .001). The TTV and TF categories achieved an area under the receiver operating characteristic curve (AUC) of 0.74 (95% CI: 0.71, 0.78), with an optimal cutoff of 151 cm3 for TTV and a TF cutoff of 10%. The sensitivity was 57% (204 of 359) and the specificity was 80% (525 of 658). TTV helped predict contributory status, with an AUC of 0.71 (95% CI: 0.67, 0.76) and an optimal cutoff greater than 37 cm3. Liver lesion volumes were significantly associated with a contributory liquid biopsy in the validation cohort. Conclusion: While correlated, TF at liquid biopsy did not accurately represent the TTV at CT.
UR - http://www.scopus.com/inward/record.url?scp=85210777225&partnerID=8YFLogxK
U2 - 10.1148/radiol.232674
DO - 10.1148/radiol.232674
M3 - Article
C2 - 39589242
AN - SCOPUS:85210777225
SN - 0033-8419
VL - 313
JO - Radiology
JF - Radiology
IS - 2
M1 - e232674
ER -